Hansford, Rebecca L.
Ouellette-Kuntz, Hélène
Griffiths, Rebecca
Hallet, Julie
Decker, Kathleen
Dawe, David E.
Kristjanson, Mark
Cobigo, Virginie
Shooshtari, Shahin
Stirling, Morgan
Kelly, Christine
Brownell, Marni
Turner, Donna
Mahar, Alyson http://orcid.org/0000-0002-6862-3760
Funding for this research was provided by:
Canadian Institutes of Health Research (162130)
Article History
Received: 16 June 2023
Accepted: 27 November 2023
First Online: 5 February 2024
Declarations
:
: RH, HOK, RG, KD, MK, VC, SS, MS, CK, MB, DT, and ALM declare no competing interests. JH has received payments for speaking honoraria from Ipsen Biopharmaceuticals, Advanced Accelerator Applications, Medtronic, and Brystol-Myers-Squibb. DED has received research grants from AstraZeneca, CIHR, CancerCare Manitoba Foundation, and the Manitoba Medical Services Foundation, as well as honoraria for education materials from Boehringer-Ingelheim and Bristol-Myers Squibb and participates as an advisory board member for AstraZeneca, Merck Canada, Jazz Pharmaceuticals, Pfizer, and Novartis. DED is a member of the Lung Cancer Canada Medical Advisory Committee, is a provincial representative on the System Performance Group for the Canadian Partnership Against Cancer, and the Medical Lead for the Frail and Older Adult initiative at CancerCare Manitoba.
: The study received ethical clearance from the University of Manitoba Health Research Ethics Board (#H2019:253) and Queen’s University Faculty of Health Sciences and Affiliated Hospitals Research Ethics Board (#EPID-691-19).
: Not applicable.
: Not applicable.
: The funding source (Canadian Institutes of Health Research; grant #162130) was not involved in any aspect of the work, including study design, data collection, data analysis, interpretation, or writing of the report.